Mineralys Therapeutics, Inc. (MLYS) company profile
Close on Nov 17, 2026Market cap $1.28BP/E –Yield –
About Mineralys Therapeutics
Pharmaceutical Preparations, SIC 2834
This biopharmaceutical company specializes in developing targeted therapies for cardiorenal metabolic conditions linked to dysregulated aldosterone. Its lead product candidate, lorundrostat, is an oral, selective aldosterone synthase inhibitor aimed at controlling conditions such as uncontrolled or resistant hypertension, chronic kidney disease, and obstructive sleep apnea. Because the candidate remains under clinical investigation and regulatory review, the enterprise currently has no approved commercial offerings, established sales segments, or direct product customers.
Operationally, the business does not operate internal manufacturing facilities and relies entirely on external contract organizations to produce raw materials and clinical supply. The provided text notes that development rights originate from a worldwide license with an Asian pharmaceutical partner and outlines clinical trials conducted across adult patient cohorts, but it specifies no facility counts, office locations, or headquarters.
Summary of the business section of Mineralys Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Mineralys Therapeutics, Inc.
- Founded
- 2019
- Headquarters
- Radnor, PA
- Address
- 150 N. Radnor Chester Road, Suite F200
- Phone
- (888) 378-6240
- Website
- mineralystx.com
- Employees
- 76, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Denver, Colorado
Stock & identifiers
- Ticker
- MLYS
- Exchange
- Nasdaq
- IPO date
- Feb 10, 2023
- Shares outstanding
- 88M, Aug 3, 2026
- Public float
- $676.00M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1933414
- CUSIP
- 603170101
- ISIN
- US6031701013
- FIGI
- BBG00ZXN1GN3
- Share class FIGI
- BBG00ZXN1GR9
- EIN
- 84-1966887
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jon Congleton | Chief Executive Officer, Director | 528,621 |
| Eric Warren | Chief Commercial Officer | 45,838 |
| David Malcom Rodman | Chief Medical Officer | 51,384 |
| James J. Ferguson III | Chief Medical Officer | 102,400 |
| Adam Scott Levy | CFO and Secretary | 48,538 |
| Lonnel Coats | Director | 12,400 |
| Kristine Peterson | Director | 12,400 |
| Brian Taylor Slingsby | Director | 7,811,918 |
| Daphne Karydas | Director | 6,200 |
| Capital Healthcare Fund LP RA | Director | 1,873,429 |
| Rajeev M. Shah | Director | 5,825,521 |
| RA Capital Nexus Fund III, L.P. | Director | 4,280,051 |
| Peter Kolchinsky | Director | – |
| Ra Capital Management, L.P. | Director | 5,456,521 |
| Glenn Sblendorio | Director | 6,200 |
| Derek DiRocco | Director | 6,200 |
| Alexander M. Gold | Director | 6,200 |
| Srinivas Akkaraju | Director | 5,877,218 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Jon Congleton President and Chief Executive Officer | $636.50K | – | $4.44M | $472.60K | $5.54M | +2% |
| Adam Levy Chief Financial Officer and Secretary | $532.00K | $25.00K | $1.32M | $323.19K | $2.20M | -23% |
| David Rodman, M.D. Chief Medical Officer | $533.00K | $25.00K | $1.32M | $323.80K | $2.20M | -23% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 10, 2023
- Offer price
- $16.00
- Securities offered
- 12,000,000
- Gross proceeds
- $192.00M
- Exchange
- Nasdaq
- First trading day
- Feb 10, 2023
- First-day close
- $18.44+15.3%
- Lock-up ends (est.)
- Aug 9, 2023
“_________________ Per Share Total Public offering price $ 16.00 $ 192,000,000 Underwriting discount (1) $ 1.12 $ 13,440,000 Proceeds, before expenses, to us $ 14.88 $ 178,560,000 (1) We refer you to “Underwriting” for additional information regarding underwriting compensation.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 76 full-time employees, of whom 39 were primarily engaged in research and development.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 10, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 6, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?